VIATRIS INC. Other Noncash Income (Expense)
VIATRIS INC. (VTRS) reported Other Noncash Income (Expense) of -$377.30 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-06
- VIATRIS INC. other noncash income (expense) for the quarter ending 2026-06-30 was -$195.00M.
- VIATRIS INC. other noncash income (expense) for the quarter ending 2026-03-31 was -$182.30M.
- VIATRIS INC. other noncash income (expense) for the quarter ending 2025-12-31 was -$133.50M.
- VIATRIS INC. other noncash income (expense) for the quarter ending 2025-09-30 was -$109.50M.
- VIATRIS INC. other noncash income (expense) for fiscal 2025 was -$969.30M, a 4260.09% decline from fiscal 2024.
- VIATRIS INC. other noncash income (expense) for fiscal 2024 was $23.30M.
- VIATRIS INC. other noncash income (expense) for fiscal 2023 was -$15.30M.
- VIATRIS INC. other noncash income (expense) for fiscal 2022 was -$434.30M.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month | Other Noncash Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$195.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$377.30M 10-Q · filed 2026-08-06 | -$510.80M derived: sum of 3 quarters · filed 2026-08-06 | -$620.30M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$182.30M 10-Q · filed 2026-05-07 | -$315.80M derived: sum of 2 quarters · filed 2026-05-07 | -$425.30M derived: sum of 3 quarters · filed 2026-05-07 | -$947.80M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$133.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$243.00M derived: sum of 2 quarters · filed 2026-02-26 | -$765.50M derived: sum of 3 quarters · filed 2026-08-06 | -$969.30M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$109.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$632.00M derived: sum of 2 quarters · filed 2026-08-06 | -$835.80M 10-Q · filed 2025-11-06 | -$993.10M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$522.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$726.30M 10-Q · filed 2026-08-06 | -$883.60M derived: sum of 3 quarters · filed 2026-08-06 | -$947.90M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | -$203.80M 10-Q · filed 2026-05-07 | -$361.10M derived: sum of 2 quarters · filed 2026-05-07 | -$425.40M derived: sum of 3 quarters · filed 2026-05-07 | -$183.50M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | -$157.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$221.60M derived: sum of 2 quarters · filed 2026-02-26 | $20.30M derived: sum of 3 quarters · filed 2026-02-26 | $23.30M 10-K · filed 2026-02-26 | -$297.70M 10-K · filed 2025-02-27 | ||
| 2024-09-30 | -$64.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $177.60M derived: sum of 2 quarters · filed 2025-11-06 | $180.60M 10-Q · filed 2025-11-06 | -$140.40M 10-Q · filed 2024-11-07 | $113.20M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-06-30 | $241.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $244.90M 10-Q · filed 2025-08-07 | -$76.10M 10-Q · filed 2024-08-08 | $177.50M derived: sum of 3 quarters · filed 2026-02-26 | $272.50M derived: sum of 4 quarters · filed 2026-02-26 | ||
| 2024-03-31 | $3.00M 10-Q · filed 2025-05-08 | -$64.40M derived: sum of 2 quarters · filed 2026-02-26 | $30.60M derived: sum of 3 quarters · filed 2026-02-26 | $17.30M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | -$67.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $27.60M derived: sum of 2 quarters · filed 2026-02-26 | $14.30M derived: sum of 3 quarters · filed 2026-02-26 | -$15.30M 10-K · filed 2026-02-26 | -$595.40M 10-K · filed 2024-02-28 | ||
| 2023-09-30 | $95.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $81.70M derived: sum of 2 quarters · filed 2024-11-07 | $52.10M 10-Q · filed 2024-11-07 | -$189.20M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | -$13.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$42.90M 10-Q · filed 2024-08-08 | -$284.20M derived: sum of 3 quarters · filed 2025-02-27 | -$473.40M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | -$29.60M 10-Q · filed 2024-05-09 | -$270.90M derived: sum of 2 quarters · filed 2025-02-27 | -$460.10M derived: sum of 3 quarters · filed 2025-02-27 | -$426.10M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | -$241.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$430.50M derived: sum of 2 quarters · filed 2025-02-27 | -$396.50M derived: sum of 3 quarters · filed 2025-02-27 | -$434.30M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$189.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$155.20M derived: sum of 2 quarters · filed 2023-11-08 | -$193.00M 10-Q · filed 2023-11-08 | -$316.60M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-06-30 | $34.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$3.80M 10-Q · filed 2023-08-07 | -$127.40M derived: sum of 3 quarters · filed 2024-02-28 | -$212.10M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-03-31 | -$37.80M 10-Q · filed 2023-05-08 | -$161.40M derived: sum of 2 quarters · filed 2024-02-28 | -$246.10M derived: sum of 3 quarters · filed 2024-02-28 | -$416.30M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2021-12-31 | -$123.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$208.30M derived: sum of 2 quarters · filed 2024-02-28 | -$378.50M derived: sum of 3 quarters · filed 2024-02-28 | -$411.80M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | -$84.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$254.90M derived: sum of 2 quarters · filed 2022-11-07 | -$288.20M 10-Q · filed 2022-11-07 | -$520.30M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-06-30 | -$170.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$203.50M 10-Q · filed 2022-08-08 | -$435.60M derived: sum of 3 quarters · filed 2023-02-27 | -$472.50M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2021-03-31 | -$33.30M 10-Q · filed 2022-05-09 | -$265.40M derived: sum of 2 quarters · filed 2023-02-27 | -$302.30M derived: sum of 3 quarters · filed 2023-02-27 | -$371.00M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | -$232.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$269.00M derived: sum of 2 quarters · filed 2023-02-27 | -$337.70M derived: sum of 3 quarters · filed 2023-02-27 | -$366.40M 10-K · filed 2023-02-27 | |||
| 2020-09-30 | -$36.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$105.60M derived: sum of 2 quarters · filed 2021-11-08 | -$134.30M 10-Q · filed 2021-11-08 | ||||
| 2020-06-30 | -$68.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$97.40M 10-Q · filed 2021-08-09 | |||||
| 2020-03-31 | -$28.70M 10-Q · filed 2021-05-10 | ||||||
| 2019-12-31 | -$360.60M 10-K · filed 2022-02-28 | ||||||
| 2018-12-31 | -$286.10M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |